Agree on both counts: Sovaldi + Olysio (no NS5a) is the most medically justifiably second-line regimen for Harvoni failures, but payers won’t go for that. So, that leaves V-Pak or Sovaldi+IFN/RBV, which is no contest.
p.s. I question whether JNJ will continue marketing Olysio in the US market for more than a couple of quarters.
Market Data 
Markets 
AI
